Contextualising Preclinical & Translational Development of ADC-C9: A Pan-Cancer Anti-ofCS ADC with Monovalent IgG Design
2:30 pm - Tuesday 24th February 2026
- Outlining development journey finetuning an ADC for an abundant pancancer that is expressed on both stromal cells and cancer cells
- Spotlighting unique design of ADC-C9 with monovalent IgG format (single armed IgG, scfv-fc) and a homogenous DAR2 through hinge region mutations
- Delving into ADC-C9 preclinical safety and efficacy profile and clinical Phase 0 findings to lay out lessons learned for translation of an ADC for a novel target
